Crossmark Global Holdings Inc. Reduces Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Crossmark Global Holdings Inc. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 75.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,955 shares of the company’s stock after selling 5,873 shares during the period. Crossmark Global Holdings Inc.’s holdings in Medpace were worth $649,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MEDP. Pallas Capital Advisors LLC boosted its stake in shares of Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after buying an additional 2,101 shares during the period. Baillie Gifford & Co. lifted its position in Medpace by 175.6% during the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock worth $4,966,000 after acquiring an additional 9,478 shares during the period. Barclays PLC grew its stake in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Medpace by 6.3% in the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock valued at $15,179,000 after purchasing an additional 2,675 shares during the period. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Medpace during the third quarter worth approximately $1,306,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Down 1.1 %

Medpace stock opened at $344.07 on Friday. The firm has a market capitalization of $10.69 billion, a PE ratio of 30.13, a P/E/G ratio of 1.77 and a beta of 1.36. Medpace Holdings, Inc. has a 52 week low of $286.76 and a 52 week high of $459.77. The firm’s 50-day simple moving average is $340.33 and its 200 day simple moving average is $355.57.

Analyst Ratings Changes

A number of research firms recently weighed in on MEDP. Robert W. Baird lifted their price objective on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Redburn Atlantic assumed coverage on shares of Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 price target on the stock. TD Cowen reduced their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.